0001884363-23-000001.txt : 20230203 0001884363-23-000001.hdr.sgml : 20230203 20230203154217 ACCESSION NUMBER: 0001884363-23-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230203 DATE AS OF CHANGE: 20230203 EFFECTIVENESS DATE: 20230203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Garuda Therapeutics, Inc. CENTRAL INDEX KEY: 0001884363 IRS NUMBER: 863018867 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-472601 FILM NUMBER: 23585571 BUSINESS ADDRESS: STREET 1: 22 STRATHMORE ROAD STREET 2: SUITE 414 CITY: NATICK STATE: MA ZIP: 02467 BUSINESS PHONE: 617-851-4586 MAIL ADDRESS: STREET 1: 22 STRATHMORE ROAD STREET 2: SUITE 414 CITY: NATICK STATE: MA ZIP: 02467 D 1 primary_doc.xml X0708 D LIVE 0001884363 Garuda Therapeutics, Inc. 215 First Street Suites 340-350 Cambridge MA MASSACHUSETTS 02142 617-851-4586 DELAWARE L Stem, LLC None Corporation true 2021 Dhvanit I Shah c/o Garuda Therapeutics, Inc. 215 First Street, Suites 340-350 Cambridge MA MASSACHUSETTS 02142 Executive Officer Director Chief Executive Officer and President Eric Aguiar c/o Garuda Therapeutics, Inc. 215 First Street, Suites 340-350 Cambridge MA MASSACHUSETTS 02142 Director Carl Gordon c/o Garuda Therapeutics, Inc. 215 First Street, Suites 340-350 Cambridge MA MASSACHUSETTS 02142 Director Rahul Singhvi c/o Garuda Therapeutics, Inc. 215 First Street, Suites 340-350 Cambridge MA MASSACHUSETTS 02142 Director Daniel Janse c/o Garuda Therapeutics, Inc. 215 First Street, Suites 340-350 Cambridge MA MASSACHUSETTS 02142 Director Raymond Kelleher c/o Garuda Therapeutics, Inc. 215 First Street, Suites 340-350 Cambridge MA MASSACHUSETTS 02142 Director Laurence Reid c/o Garuda Therapeutics, Inc. 215 First Street, Suites 340-350 Cambridge MA MASSACHUSETTS 02142 Director Biotechnology Decline to Disclose 06b false 2023-01-23 false true false 0 62898094 62124935 773159 false 13 0 0 0 false Garuda Therapeutics, Inc. /s/ Dhvanit I. Shah Dhvanit I. Shah Chief Executive Officer and President 2023-02-03